SEP Analytical (Shanghai) Co. Ltd. (301228) - Net Assets
Based on the latest financial reports, SEP Analytical (Shanghai) Co. Ltd. (301228) has net assets worth CN¥606.89 Million CNY (≈ $88.81 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥1.02 Billion ≈ $148.63 Million USD) and total liabilities (CN¥408.85 Million ≈ $59.83 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore balance sheet size of SEP Analytical (Shanghai) Co. Ltd. for the complete picture of this company's asset base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥606.89 Million |
| % of Total Assets | 59.75% |
| Annual Growth Rate | 10.61% |
| 5-Year Change | 39.55% |
| 10-Year Change | N/A |
| Growth Volatility | 46.66 |
SEP Analytical (Shanghai) Co. Ltd. - Net Assets Trend (2019–2025)
This chart illustrates how SEP Analytical (Shanghai) Co. Ltd.'s net assets have evolved over time, based on quarterly financial data. Check tangible net worth ratio of SEP Analytical (Shanghai) Co. Ltd. to evaluate the tangible quality of the company's equity base.
Annual Net Assets for SEP Analytical (Shanghai) Co. Ltd. (2019–2025)
The table below shows the annual net assets of SEP Analytical (Shanghai) Co. Ltd. from 2019 to 2025. For live valuation and market cap data, see SEP Analytical (Shanghai) Co. Ltd. market cap and net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥620.10 Million ≈ $90.74 Million |
-21.72% |
| 2024-12-31 | CN¥792.19 Million ≈ $115.92 Million |
-13.21% |
| 2023-12-31 | CN¥912.78 Million ≈ $133.57 Million |
-5.62% |
| 2022-12-31 | CN¥967.12 Million ≈ $141.52 Million |
+117.64% |
| 2021-12-31 | CN¥444.36 Million ≈ $65.02 Million |
+13.49% |
| 2020-12-31 | CN¥391.53 Million ≈ $57.29 Million |
+15.63% |
| 2019-12-31 | CN¥338.60 Million ≈ $49.55 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to SEP Analytical (Shanghai) Co. Ltd.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 308.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | CN¥731.36 Million | 119.46% |
| Total Equity | CN¥612.23 Million | 100.00% |
SEP Analytical (Shanghai) Co. Ltd. Competitors by Market Cap
The table below lists competitors of SEP Analytical (Shanghai) Co. Ltd. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Marcus & Millichap Inc
NYSE:MMI
|
$1.11 Billion |
|
Ituran Location and Control Ltd
NASDAQ:ITRN
|
$1.11 Billion |
|
Tong Hsing Electronic Industries Ltd
TW:6271
|
$1.11 Billion |
|
Vizsla Silver Corp.
TO:VZLA
|
$1.11 Billion |
|
Darma Henwa Tbk
JK:DEWA
|
$1.11 Billion |
|
XPLR Infrastructure LP Unit
NYSE:XIFR
|
$1.11 Billion |
|
Blue Jet Healthcare Limited
NSE:BLUEJET
|
$1.11 Billion |
|
Faraday Copper Corp.
TO:FDY
|
$1.11 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in SEP Analytical (Shanghai) Co. Ltd.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 720,784,024 to 612,234,817, a change of -108,549,207 (-15.1%).
- Net loss of 68,001,946 reduced equity.
- Dividend payments of 1,596,572 reduced retained earnings.
- Other factors decreased equity by 38,950,690.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥-68.00 Million | -11.11% |
| Dividends Paid | CN¥1.60 Million | -0.26% |
| Other Changes | CN¥-38.95 Million | -6.36% |
| Total Change | CN¥- | -15.06% |
Book Value vs Market Value Analysis
This analysis compares SEP Analytical (Shanghai) Co. Ltd.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 12.35x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 17.38x to 12.35x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | CN¥3.63 | CN¥63.00 | x |
| 2020-12-31 | CN¥4.16 | CN¥63.00 | x |
| 2021-12-31 | CN¥4.72 | CN¥63.00 | x |
| 2022-12-31 | CN¥7.58 | CN¥63.00 | x |
| 2023-12-31 | CN¥6.72 | CN¥63.00 | x |
| 2024-12-31 | CN¥6.01 | CN¥63.00 | x |
| 2025-12-31 | CN¥5.10 | CN¥63.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently SEP Analytical (Shanghai) Co. Ltd. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -11.11%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -17.07%
- • Asset Turnover: 0.38x
- • Equity Multiplier: 1.72x
- Recent ROE (-11.11%) is below the historical average (1.77%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | 21.55% | 23.60% | 0.61x | 1.51x | CN¥37.70 Million |
| 2020 | 12.77% | 13.29% | 0.58x | 1.67x | CN¥10.37 Million |
| 2021 | 11.87% | 11.87% | 0.63x | 1.59x | CN¥7.94 Million |
| 2022 | -1.98% | -5.11% | 0.28x | 1.37x | CN¥-108.89 Million |
| 2023 | -11.60% | -25.02% | 0.30x | 1.53x | CN¥-174.20 Million |
| 2024 | -9.13% | -14.88% | 0.39x | 1.57x | CN¥-137.87 Million |
| 2025 | -11.11% | -17.07% | 0.38x | 1.72x | CN¥-129.23 Million |
Industry Comparison
This section compares SEP Analytical (Shanghai) Co. Ltd.'s net assets metrics with peer companies in the Scientific & Technical Instruments industry.
Industry Context
- Industry: Scientific & Technical Instruments
- Average net assets among peers: $1,500,158,816
- Average return on equity (ROE) among peers: 10.08%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| SEP Analytical (Shanghai) Co. Ltd. (301228) | CN¥606.89 Million | 21.55% | 0.67x | $1.11 Billion |
| Beijing BDStar Navigation Co Ltd (002151) | $849.33 Million | 5.08% | 0.99x | $2.32 Billion |
| Oriental Times Media Corp (002175) | $258.65 Million | 2.09% | 0.47x | $444.66 Million |
| Changchun UP Optotech Co Ltd (002338) | $890.24 Million | 4.58% | 0.11x | $1.37 Billion |
| Nanjing Sciyon Automation Group Co Ltd (002380) | $949.47 Million | 4.48% | 0.18x | $1.01 Billion |
| Beijing UniStrong Science & Technology Co Ltd (002383) | $1.84 Billion | 3.30% | 0.36x | $756.20 Million |
| Jiangsu Changfa Refrigeration Co Ltd (002413) | $4.96 Billion | -4.85% | 0.30x | $1.57 Billion |
| Wuhan Guide Infrared Co Ltd (002414) | $126.98 Million | 64.90% | 0.90x | $7.97 Billion |
| Shenzhen Jieshun Science and Technology Industry Co Ltd (002609) | $2.13 Billion | 6.69% | 0.30x | $732.53 Million |
| Beijing SDL Technology Co Ltd (002658) | $1.36 Billion | 14.67% | 0.20x | $680.99 Million |
| Shenzhen Soling Industrial Co Ltd (002766) | $1.65 Billion | -0.14% | 1.22x | $497.00 Million |
About SEP Analytical (Shanghai) Co. Ltd.
SEP Analytical (Shanghai) Co., Ltd. engages in the provision of third-party testing services in China. It offers soil, ground water and wastewater, seawater, solid waste, sludge, edible agricultural products, food, cosmetics, textiles, toys and children's products, occupational health, medicine, and other testing services related to human health. The company is also involved in the provision of i… Read more